The estimated Net Worth of Edward M. Md Kaye is at least 6.64 百万$ dollars as of 20 May 2024. Dr Kaye owns over 42,350 units of Stoke Therapeutics stock worth over 397,980$ and over the last 12 years he sold STOK stock worth over 5,286,881$. In addition, he makes 958,046$ as CEO & Director at Stoke Therapeutics.
Dr has made over 19 trades of the Stoke Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 42,350 units of STOK stock worth 653,461$ on 20 May 2024.
The largest trade he's ever made was exercising 50,000 units of Stoke Therapeutics stock on 16 December 2019 worth over 30,000$. On average, Dr trades about 4,898 units every 42 days since 2012. As of 20 May 2024 he still owns at least 27,000 units of Stoke Therapeutics stock.
You can see the complete history of Dr Kaye stock trades at the bottom of the page.
Dr. Edward M. Kaye is the CEO & Director at Stoke Therapeutics.
As the CEO & Director of Stoke Therapeutics, the total compensation of Dr Kaye at Stoke Therapeutics is 958,046$. There are 1 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of 1,176,400$.
Dr Kaye is 72, he's been the CEO & Director of Stoke Therapeutics since . There are no older and 20 younger executives at Stoke Therapeutics.
Edward's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.
Over the last 5 years, insiders at Stoke Therapeutics have traded over 49,612,288$ worth of Stoke Therapeutics stock and bought 4,288,550 units worth 94,976,062$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Investments, Lpwong Roderic...、Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of 1,639,987$. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth 6,000$.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics executives and other stock owners filed with the SEC include: